Latest Oncology News

Pedmark Reduces Ototoxicity Risk in Cisplatin-Treated Pediatric Solid Tumors

September 29th 2022

Ashling Wahner

Nilay Shah, MD, discusses the importance of the FDA approval of sodium thiosulfate for pediatric patients with solid tumors, the favorable toxicity profile of the agent, and how clinical trial findings may inform future care in this population.

FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma

September 28th 2022

Chris Ryan

The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.

Giredestrant Shows Numerical PFS Benefit Vs Endocrine Monotherapy in ER+ Metastatic Breast Cancer

September 28th 2022

Kristi Rosa

Giredestrant provided a numerical, but not statistically significant, improvement in progression-free survival over physician’s choice of endocrine therapy in patients with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer, according to data from the phase 2 acelERA BC study.

Durvalumab/Chemo Combination and Other Novel Treatments Arise in Biliary Tract Cancers

September 28th 2022

Ashling Wahner

Chemoimmunotherapy combinations, along with therapies targeting IDH1, FGFR2, and HER2 mutations, are ushering in a new era of treatment for biliary tract cancers.

Gavo-cel Elicits Clinical Benefit in Solid Tumors, Including Ovarian Cancer and Mesothelioma

September 28th 2022

Caroline Seymour

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

Latest Oncology Videos

Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

Management of Carcinoid Syndrome-Related Symptoms

Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Biliary Tract Cancers: Staging and Clinicopathologic Features

Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

Challenges in Diagnosing Biliary Tract Cancers

Dr. Ansell on the LOTIS-2 Trial of Loncastuximab Tesirine in R/R DLBCL

Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care

Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia Vera

Dr. Girard on Examining the Real-World Effectiveness of Lurbinectedin in SCLC

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

All Oncology News

NYU Langone Health Receives Awards for Outstanding Quality & Safety

September 28th 2022

Perlmutter Cancer Center at NYU Langone

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc.

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors

September 28th 2022

Caroline Seymour

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Continuous Chemotherapy Improves TTF But Not OS in ER+/HER2- Advanced Breast Cancer

September 28th 2022

Caroline Seymour

Vinorelbine plus cyclophosphamide and capecitabine led to a significant improvement in time to treatment failure compared with paclitaxel alone in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Pyrotinib Plus Trastuzumab/Docetaxel Prolongs PFS in HER2+ Metastatic Breast Cancer

September 28th 2022

Kristi Rosa

The addition of pyrotinib to trastuzumab and docetaxel significantly improved progression-free survival vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer.

Pafolacianine Detects Microlesions in Folate Receptor–Positive Ovarian Cancer

September 27th 2022

Jason Harris

Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.

Tepotinib/Osimertinib Combo Induces ORR Benefit in EGFR-mutated NSCLC

September 27th 2022

Ashling Wahner

Julien Maziéres, MD, PhD, explains the importance of defining a second-line standard of care in the EGFR-mutated non–small cell lung cancer population, highlights the long-term benefits seen with tepotinib plus osimertinib, and previews the next steps that should be taken toward more individualized patient care.

Sunvozertinib Generates Responses in Platinum-Pretreated EGFR Exon 20–Mutated NSCLC

September 27th 2022

Ryan Scott

Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.

Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening

September 27th 2022

Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which bring health education and free screenings for many cancer types to South Florida communities in need, are offering prostate-specific antigen screening for prostate cancer.

FDA Grants Fast Track Designation to AL102 for Progressing Desmoid Tumors

September 27th 2022

Chris Ryan

The FDA has granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.

Desmoid Tumors: The Tumor That Isn’t a Cancer

September 27th 2022

Jason Harris

Desmoid tumors, also known as aggressive fibromatosis, share some characteristics with cancers, specifically unchecked cell growth. However, it is not accurate to call them a cancer.

Pembrolizumab Plus Chemo Maintains Survival Benefit in Treatment-Naïve Nonsquamous NSCLC

September 27th 2022

Kristi Rosa

Pembrolizumab plus platinum/pemetrexed continued to demonstrate an overall survival and progression-free survival benefit vs platinum/pemetrexed alone in patients with previously untreated, metastatic squamous non–small cell lung cancer.

Immunotherapy and Targeted Therapy Approaches Drive Advances in Biliary Tract Cancer

September 26th 2022

Ashling Wahner

Flavio G. Rocha, MD, FACS, FSSO, discusses the types of biliary tract cancer and what has been learned about them, explains the effects of systemic therapy on surgery, and relays remaining questions pertaining to the efficacy of immunotherapy.

Fruquintinib Provides Significant Survival Benefits in Heavily Pretreated mCRC

September 26th 2022

Ryan Scott

Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.

Deol on the Importance of a Well-Rounded Fellowship Experience

September 26th 2022

OncLive Staff

Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he helps fellows deal with grief.

AZD4635 Plus Durvalumab or Oleclumab Has Minimal Clinical Activity in mCRPC

September 26th 2022

Ryan Scott

The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.

See All News